Company intelligence / Profile preview

Hefei Kangnuo Biopharmaceutical

Hefei, Anhui Sheng, Chinadnb.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has at least one small molecule drug in the clinic, with a focus on hemic and lymphatic as well as cardiovascular diseases. No detailed clinical results are publicly available. One literature reference describes optimization of extraction technology for Qingremingmu Capsule, but this appears to be more related to process development than late-stage clinical data.

Therapeutic areas: CardiovascularHematology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

doxofylline

Commercial

Indications: Chronic obstructive pulmonary disease, Bronchial asthma, Bronchospasm

Beyond the preview

Go deeper on Hefei Kangnuo Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hefei Kangnuo Biopharmaceutical.

Explore the full profile